Burcon NutraScience Corporation heads into the final week of April with two stories running at once — a sharp squeeze in short positioning and an operating inflection that is starting to attract real buying interest.
The operational news broke on April 21. Burcon announced record production output, a customer base that has grown to more than 20 buyers, and management's active evaluation of additional capacity expansion. For a company that spent years developing its canola and pea protein technology platform, crossing from pilot-scale to commercially meaningful throughput is a meaningful shift. That announcement coincided almost precisely with the biggest spike in short interest over the past 30 days — shorts peaked at more than 4,000 shares on April 22 — before collapsing. By April 28, estimated short interest had fallen to roughly 609 shares, a 57% decline on the week and a 64% drop over the month. At 0.005% of free float, the short position is too small to carry much market significance on its own. The story here is not the shorts — it is the speed at which they retreated.
The borrow market reflects the same rapid unwinding. Cost to borrow has fallen sharply from a 30-day high near 5.4% in early March to around 1.7% now — roughly half the level of three weeks ago. Availability remains at normal levels, with no signs of scarcity in the lending pool. The ORTEX short score has drifted lower alongside the unwind, settling at 43.2 from a recent high of 45.5 on April 22 — consistent with a stock where short pressure is fading rather than building. Borrow availability is comfortably loose, and the lending market is not signalling any crowding dynamic.
Price action has followed the positioning shift. BU closed at CAD 2.37 on April 28, a 2.6% gain on the week and a 24.7% advance over the past month. That monthly move is worth noting in context: the stock was trading at sub-C$0.10 levels as recently as early 2025, judging by the insider trade history, which shows director John Vassallo accumulating hundreds of thousands of shares at C$0.06–C$0.07 across late 2024 and into March 2025. Vassallo now holds 12.6% of shares outstanding. The largest single holder, PT International Development, holds 14.7% with no reported change — a concentrated book typical of early-stage commercialisation stories.
Ownership concentration is notably high. The top two holders together control more than 27% of shares outstanding. Beyond Vassallo's consistent accumulation at much lower prices, the most recent insider trade was a sell — Independent Director Richard Nazur disposed of just under 30,000 shares in March at C$1.60, below the current price. That is a modest position reduction rather than a signal of fundamental concern, but it is the only open-market sale in the recent record. On the buy side, April 29 brought the announcement of a new board director appointment, adding fresh governance capacity as the company evaluates expansion.
The next formal catalyst is an earnings event scheduled for June 25. The limited earnings history shows a mixed pattern — the most recent Q1 release in February produced a 1-day decline of about 1.8%, though the stock recovered strongly over the following five days, gaining roughly 8.8%. That post-release recovery pattern has appeared across the last several reports. The pea protein sector tailwind is visible in the news flow too: third-party research projects the global pea protein market reaching $4 billion by 2033, and Burcon is now a commercial-scale participant rather than a pure research story. What to watch into June is whether production volumes continue to scale and whether the customer count grows beyond the current 20+ — those two numbers will frame how the Street eventually prices a company that, for now, carries an enterprise value just above C$36 million.
See the live data behind this article on ORTEX.
Open BU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
